Research News
(Myers K et al. 2017) Mortality in Dravet syndrome is recognized at 15-20% by adulthood. Approximately half of those deaths are due to SUDEP, while about 1/4 are due to status epilepticus (SE). This study looked closely at that second group, those who died from SE, examining the characteristics of 5 patients from Australia who […]
(Jensen, et al. 2017). A team of physicians from Washington, the United Kingdom, Colorado, and Zogenix, Inc. reviewed the published literature on the burden of Dravet syndrome (DS) on caregivers and families. Instead of examining diagnostic criteria, treatment/management, seizure control, etc., they looked specifically for how DS affects the caregiver and families both humanistically and economically.
(Wirrell, et al. 2017). A panel of experts on Dravet syndrome including 13 physicians and 5 family members of patients with Dravet syndrome in North America answered a series of in-depth surveys about the presentation, diagnosis, and treatment of Dravet syndrome. Consensus was obtained in many areas including presentation during the first years of life;
(Aljaafari, et. al. 2017). In this brief communication, published in Epilepsia, the authors examined the motor differences between 14 adult patients with Dravet syndrome (DS) and 14 adult patients with Lennox-Gastaut syndrome (LGS). They chose Lennox-Gastaut because previous findings showed that adult patients with DS exhibited early-onset parkinsonian features, and they wanted to determine whether
(Griffin, et. al 2017). Building on previous drug screening in a Dravet syndrome model of zebrafish that identified clemizole, a histamine (H1) receptor antagonist, as having anti-epileptic properties, this study sought to further examine the mechanisms of clemizole\’s action and expand the class of serotonin-acting compounds to include, among others, the FDA-approved drugs lorcaserin (Belviq) and
Clemizole and modulators of serotonin signalling suppress seizures in Dravet syndrome Read More »
This website is made possible through educational grants from our partners. Partners did not have a role in developing content. The information you obtain at this site is not intended to be medical advice, please read our medical disclaimer. Thank you to:
© Copyright 2024 | Dravet Syndrome Foundation | All Rights Reserved
Every gift to our Annual Campaign before December 31 will be matched, dollar-for-dollar, up to $30,000. Don’t miss this chance to make twice the difference for families living with Dravet syndrome!
